Evidence map›Paper›PMID 31376275›Full record

ArticleJMIR research protocols2019

Assessing the Content Validity of a New Patient-Reported Measure of Barriers to Antiretroviral Therapy Adherence for Electronic Administration in Routine HIV Care: Proposal for a Web-Based Delphi Study.

Kim Engler, Sara Ahmed, David Lessard, Serge Vicente, Bertrand Lebouché

Registry-linked trialAbstract read
In one paragraph

Article in JMIR research protocols, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04702412 (Implementation of an Electronic Patient-reported Measure of Barriers to Antiretroviral Therapy Adherence With the Opal Patient Portal), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04702412 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Implementation of an Electronic Patient-reported Measure of Barriers to Antiretroviral Therapy Adherence With the Opal Patient Portal: a Mixed Method Type 3 Hybrid Pilot Study at a Large Montreal HIV Clinic

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2021 to 2022Enrolled30ConditionsHIV InfectionsArmsThe Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Use of genotypic HIV DNA testing: a DELPHI-type consensus.The Journal of antimicrobial chemotherapy · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kim EnglerCenter for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-8364-7421
Sara AhmedCenter for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-5172-6790
David LessardCenter for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-1151-3763
Serge VicenteDepartment of Mathematics and Statistics, University of Montreal, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-6478-4308
Bertrand LebouchéCenter for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-1273-9393

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdherence to lifesaving antiretroviral therapy (ART) for HIV infection remains a challenge for many patients. Routine screening for barriers to ART adherence could help make HIV care more patient-centered and prevent virologic rebound or failure. Our team is currently developing a new HIV-specific patient-reported outcome measure (PROM) of these barriers for use in Canada and France along with a digital app for its electronic administration. In our previous work, we developed the PROM's multidimensional conceptual framework and generated 100 English items, which have been translated to French.

objectiveThis study aims to use a Web-based Delphi to help validate and select the content of this new HIV-specific PROM, based on the perspective of anglophone and francophone patients and providers in Canada and France. Here, we present the proposal for this Delphi.

methodsThis modified Delphi will involve a diverse panel of patients (n=32) and providers (n=52) recruited especially from the 9 sites of the PROM development study (site locations in Canada: Montreal, Toronto, Vancouver; in France: Paris, Nantes, Clermont-Ferrand, Saint-Martin, Cayenne). Overall, 2 rounds of Web-based questionnaires will be conducted. The threshold for consensus is set at 60% and will determine which items are carried forward to the second round. Per item, 3 aspects will be rated: importance as a barrier to ART adherence, relevance for HIV care, and clarity. In both rounds, space will be available for free text comments. Overall comprehensiveness will be assessed in the second round.

resultsThis study has undergone a methodological review by experts in patient-oriented research. It has received approval from a research ethics board of the McGill University Health Centre. It is financially supported, in part, by the Canadian Institutes of Health Research's Strategy for Patient-Oriented Research-Quebec Support Unit (M006). As of May 21, 2019, 15 people living with HIV and 25 providers completed the first round of the Delphi (24 from Canada and 16 from France).

conclusionsTo our knowledge, this is the first Delphi to seek consensus on the most relevant and clinically actionable barriers to ART adherence, collecting opinions on an extensive list of barriers. Drawing on a relatively large and diverse panel of HIV patients and providers, it essentially engages key stakeholders in decision making about the PROM's final content, helping to ensure its utility and adoption. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/12836.

Indexed as

antiretroviral therapy, highly activeCanadaDelphi techniqueFranceHIVmedication adherencepatient-reported outcome measurestakeholder participation

Identifiers

PMID31376275
PMCPMC6696859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.